Close

Covidien announced FDA approval for its generic myocardial perfusion imaging kit

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...
Covidien a leading global provider of healthcare products, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company's Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's generic product is pharmaceutically equivalent to Cardiolite(R)(1), a myocardial perfusion imaging agent used for detecting coronary artery disease. The branded product is utilized in nearly 60 percent of the 15 million myocardial perfusion imaging studies performed in the U.S. annually.(2)

Covidien a leading global provider of healthcare products, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company's Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's generic product is pharmaceutically equivalent to Cardiolite(R)(1), a myocardial perfusion imaging agent used for detecting coronary artery disease. The branded product is utilized in nearly 60 percent of the 15 million myocardial perfusion imaging studies performed in the U.S. annually.(2)

With FDA approval of the ANDA, which was filed by the Company's Mallinckrodt subsidiary, Covidien's generic product is now available for customers in the United States. The Company's generic product also has recently received final regulatory approval in Denmark, Germany and the United Kingdom.

Steve Hanley, President, Imaging Solutions, Covidien said, With the launch of our generic product, we are broadening the selection of nuclear cardiology solutions in our product portfolio. This new generic kit is a demonstration of Covidien's ongoing investment and commitment to provide valuable diagnostic imaging agents to the nuclear medicine community.

Latest stories

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back